We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

43 hedge funds and large institutions have $755M invested in Design Therapeutics in 2021 Q1 according to their latest regulatory filings, with 43 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

47.87% more ownership

Funds ownership: 0% → 47.87% (+48%)

Holders
43
Holders Change
+43
Holders Change %
–
% of All Funds
0.76%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
43
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CAM
Cormorant Asset Management
Massachusetts
+$173M
2
LGM
Logos Global Management
California
+$92.2M
3
Citadel Advisors
Citadel Advisors
Florida
+$85.5M
4
RCM
RA Capital Management
Massachusetts
+$73.8M
5
ACA
Avoro Capital Advisors
New York
+$49.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$146M +$173M +5,114,850 New
LGM
2
Logos Global Management
California
$81.7M +$92.2M +2,732,501 New
Citadel Advisors
3
Citadel Advisors
Florida
$75.8M +$85.5M +2,534,703 New
RCM
4
RA Capital Management
Massachusetts
$65.4M +$73.8M +2,186,636 New
BBA
5
Baker Bros. Advisors
New York
$43M +$48.5M +1,436,636 New
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$41.9M +$48.4M +1,435,254 New
ACA
7
Avoro Capital Advisors
New York
$39.7M +$49.5M +1,468,318 New
EC
8
EcoR1 Capital
California
$34M +$38.4M +1,137,940 New
Wellington Management Group
9
Wellington Management Group
Massachusetts
$33.5M +$38.5M +1,141,985 New
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$32.7M +$40M +1,186,636 New
Fidelity Investments
11
Fidelity Investments
Massachusetts
$29.9M +$33.7M +1,000,000 New
BlackRock
12
BlackRock
New York
$23.7M +$26.7M +791,019 New
VC
13
Vivo Capital
California
$15.9M +$17.9M +530,991 New
AG
14
Artal Group
Luxembourg
$12M +$13.5M +400,000 New
EAM
15
Eventide Asset Management
Massachusetts
$12M +$13.5M +400,000 New
RSCM
16
Rock Springs Capital Management
Maryland
$9.79M +$11M +327,250 New
HA
17
HHLR Advisors
Cayman Islands
$8.4M +$9.48M +280,991 New
Millennium Management
18
Millennium Management
New York
$7.57M +$8.53M +253,037 New
OCA
19
Octagon Capital Advisors
New York
$7.47M +$8.43M +250,000 New
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$5.98M +$6.75M +200,000 New
Norges Bank
21
Norges Bank
Norway
$5.98M +$6.75M +200,000 New
Vanguard Group
22
Vanguard Group
Pennsylvania
$3.74M +$4.22M +124,991 New
Principal Financial Group
23
Principal Financial Group
Iowa
$3.21M +$3.62M +107,408 New
Goldman Sachs
24
Goldman Sachs
New York
$2.5M +$2.81M +83,450 New
CS
25
Credit Suisse
Switzerland
$1.84M +$2.07M +61,428 New
1
2

DSGN Hedge Fund Activity: Q1 2021 in Review

43 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2021, worth a combined $755M.

Buyers outnumbered sellers: 43 funds opened new DSGN positions and 0 closed out — a net gain of 43 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $173M.

  • 43 institutional investors held Design Therapeutics (DSGN) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $755M of Design Therapeutics stock for Q1 2021.
  • 43 funds opened new Design Therapeutics positions in Q1 2021 and 0 closed out, a net change of +43 holders.
  • The largest Design Therapeutics buyer in Q1 2021 was Cormorant Asset Management, an estimated $173M added.

Based on aggregated 13F filings for Q1 2021.